FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs

Century Therapeutics, Inc. (NASDAQ:IPSC) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for Century Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings of ($1.18) per share for the year. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other research firms have also recently weighed in on IPSC. Chardan Capital decreased their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler decreased their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Price Performance

Shares of IPSC opened at $0.77 on Friday. The firm has a 50 day simple moving average of $0.98 and a two-hundred day simple moving average of $1.36. The company has a market cap of $65.86 million, a P/E ratio of -0.42 and a beta of 1.73. Century Therapeutics has a one year low of $0.68 and a one year high of $5.51.

Institutional Trading of Century Therapeutics

Several institutional investors have recently modified their holdings of IPSC. SG Americas Securities LLC bought a new stake in Century Therapeutics during the third quarter valued at $27,000. State Street Corp boosted its position in Century Therapeutics by 7.4% during the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after acquiring an additional 57,323 shares during the last quarter. Wellington Management Group LLP bought a new stake in Century Therapeutics during the third quarter valued at $284,000. Barclays PLC boosted its position in Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after acquiring an additional 45,797 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Century Therapeutics by 3.5% during the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after acquiring an additional 32,614 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.